Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.
about
Killing of Trypanozoon Parasites by the Equine Cathelicidin eCATH1.Modulatory effects of vasoactive intestinal peptide on intestinal mucosal immunity and microbial community of weaned piglets challenged by an enterotoxigenic Escherichia coli (K88)Efficacy of VIP as Treatment for Bacteria-Induced Keratitis Against Multiple Pseudomonas aeruginosa StrainsDietary grape seed proanthocyanidins (GSPs) improve weaned intestinal microbiota and mucosal barrier using a piglet modelLulling immunity, pain, and stress to sleep with cortistatin.Modulation of the main porcine enteric neuropeptides by a single low-dose of lipopolysaccharide (LPS) Salmonella Enteritidis.Design, Recombinant Fusion Expression and Biological Evaluation of Vasoactive Intestinal Peptide Analogue as Novel Antimicrobial Agent.Influence of Proline Substitution on the Bioactivity of Mammalian-Derived Antimicrobial Peptide NK-2.Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats.Role of vasoactive intestinal peptide in Aspergillus fumigatus-infected cornea.Vasoactive intestinal peptide degradation might influence Interleukin-17 expression in cardiac chagasic patientsThe Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis
P2860
Q30755619-556E0FB1-5334-4957-91E2-2F8E7B83B1DAQ34015572-A2EE654C-917D-4F52-AAC4-9E06646E8465Q36232558-5296765C-3461-40D1-9AB5-1C8DDD304943Q37696999-57E48EB4-66D6-4B9F-949C-33F3135BCDB8Q38464963-6B461219-71E1-45AB-92F6-24F143C55CD3Q47097224-0E66B376-FE2C-4161-AA85-E4193699CF91Q47405151-D9C296B5-B8E4-4C95-92DC-D9DF2C68ECF1Q47635990-809981FA-68DE-4F1C-94D3-EFC76F41A8A8Q49885466-478D38AE-2A6E-43F3-85E4-0F06B21D2A18Q50321412-7E828E01-B08D-497F-A582-DFBCC9C53AB4Q58583576-2A76F3AD-5278-4202-B118-7E52A21D8501Q58805868-195F55F7-7F8F-4109-AC7E-F56618FDC0C6
P2860
Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Therapeutic efficacy of stable ...... nal peptide against pathogens.
@ast
Therapeutic efficacy of stable ...... nal peptide against pathogens.
@en
type
label
Therapeutic efficacy of stable ...... nal peptide against pathogens.
@ast
Therapeutic efficacy of stable ...... nal peptide against pathogens.
@en
prefLabel
Therapeutic efficacy of stable ...... nal peptide against pathogens.
@ast
Therapeutic efficacy of stable ...... nal peptide against pathogens.
@en
P2093
P2860
P50
P356
P1476
Therapeutic efficacy of stable ...... inal peptide against pathogens
@en
P2093
Antonio Cavazzuti
Francisco O'Valle
Irene Forte-Lago
Jenny Campos-Salinas
Marta Caro
P2860
P304
14583-14599
P356
10.1074/JBC.M114.560573
P407
P577
2014-04-04T00:00:00Z